Armistice Capital LLC Increases Holdings in Cencora, Inc. $COR

Armistice Capital LLC grew its holdings in Cencora, Inc. (NYSE:COR) by 298.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,000 shares of the company’s stock after purchasing an additional 20,967 shares during the period. Armistice Capital LLC’s holdings in Cencora were worth $9,457,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of COR. AustralianSuper Pty Ltd bought a new stake in shares of Cencora in the third quarter worth $26,191,000. Chilton Investment Co. Inc. purchased a new position in Cencora during the third quarter valued at $459,000. Lansforsakringar Fondforvaltning AB publ lifted its position in shares of Cencora by 5.4% in the third quarter. Lansforsakringar Fondforvaltning AB publ now owns 60,254 shares of the company’s stock valued at $18,831,000 after acquiring an additional 3,073 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Cencora by 3.8% in the fourth quarter. Nordea Investment Management AB now owns 1,256,356 shares of the company’s stock valued at $426,715,000 after acquiring an additional 45,712 shares in the last quarter. Finally, Groupama Asset Managment purchased a new position in shares of Cencora in the third quarter valued at about $1,225,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on COR. Citigroup decreased their target price on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. William Blair initiated coverage on Cencora in a research note on Tuesday, April 28th. They set a “market perform” rating on the stock. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Weiss Ratings cut Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Finally, Evercore set a $360.00 price objective on Cencora in a research note on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $374.00.

Cencora Stock Performance

Shares of COR opened at $277.10 on Thursday. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The stock has a fifty day moving average price of $286.62 and a 200-day moving average price of $325.41. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The firm has a market cap of $53.91 billion, a PE ratio of 21.25, a P/E/G ratio of 1.52 and a beta of 0.59.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the prior year, the company posted $4.42 EPS. The business’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio (DPR) is 18.40%.

Cencora declared that its board has authorized a share buyback plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.